Back to News
Market Impact: 0.5
Akeso Reports Positive Overall Survival Results For Ivonescimab In First-Line PD-L1-Positive NSCLC
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Akeso reported positive overall-survival results from the Phase III HARMONi-2 trial of ivonescimab versus pembrolizumab in first-line PD-L1-positive locally advanced or metastatic non-small cell lung cancer. The positive late-stage survival data strengthen ivonescimab's clinical profile in a major oncology indication and could support regulatory and commercial prospects.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.70
More News
- Nasdaq Nears Correction as Amazon, Alphabet, Intel Disappoint Wall Street
- Binance’s $6.3 Billion Cyber Heist Shows Crypto Vulnerabilities
- Big Oil Scores $56 Billion Windfall on Spiking Fuel Prices
- Chevron speeds ahead in Venezuela while Exxon urges caution with a ‘little pinch of salt’
- Backbone of a beast – charting Nvidia's rise to networking titan
- OpenAI raises just $11bn of $30bn target as AI investor appetite cools